Treatment progress of follicular lymphoma: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.01.003
- VernacularTitle:滤泡淋巴瘤治疗进展:第56届美国血液学会年会报道
- Author:
Ruize CHEN
;
Wei XU
;
Jianyong LI
- Publication Type:Journal Article
- Keywords:
Follicular lymphoma;
Treatment progression;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(1):6-8
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is a kind of indolent Non-Hodgkin lymphoma (NHL),which stems from follicle germinal center.A lot of research reported the latest development about treatment of FL in the 56th American Society of Hematology (ASH) annual meeting.Effect of radiotherapy for patients at low stage was determined,while the outcomes of clinical trials in which monoclonal antibody (GA101) in combination with chemotherapy for the advanced stage FL were exciting.In rituximab era,relapsed/refractory FL patients who receive stem cell transplantation could acquire preferable remissions.Several novel drugs (inhibitor of BTK or PI3K) for relapsed/refractory FL played a role of guidepost with the progression of corresponding trials.
